emocha’s program transforms non-adherent patients into adherent patients.
Remote Pharmacist Medication Review
Pharmacists perform a Comprehensive Medication Review at program kickoff to resolve medication issues related to nonadherence.
Asynchronous Video Check‑In
A daily, asynchronous video appointment creates accountability and offers insights into patient health and behavior.
Daily Engagement & Support
emocha’s engagement playbook is a hybrid model that combines human engagement and scalable algorithms.
Medication Problem Intervention
emocha confirms that patients follow correct administration & technique, and addresses issues including side effects.
Financial, social, and motivational incentives– developed to align with program goals – help kickstart behavior change.
emocha solves medication adherence through a CDC-endorsed, validated model called DOT.
DOT is the only technique proven to consistently secure adherence rates greater than 90 percent, and address behavior issues, medication problems, and social determinants through daily interaction. emocha holistically scales this practice through the power of people and technology.
Who We Help
emocha is the standard of care in more than 60 health departments globally, often complementing in-person DOT.
Medication adherence reduces the risk that transplanted organs fail, avoiding costly and difficult complications such as rejection episodes, infection, graft failure, and retransplantation.
Patients who adhere to medications to treat substance use disorder are at reduced risk of overdose and are less likely to use illicit drugs.
Patients with poorly managed diabetes are at higher risk of life-threatening complications, hospitalizations, and ER visits, in addition to more expensive comorbidities.
COPD patients who adhere to maintenance medication, and master proper inhaler technique, can avoid complications.
Increased healthcare utilization is directly tied to non-adherence to maintenance medications for asthma, including incorrect technique and decreased motivation.